0
Editorials |

Omalizumab in Asthma: Is the Therapeutic Window Too Small?

K. Deepa Bhat, MD; William J. Calhoun, MD
Author and Funding Information

From the Department of Internal Medicine, University of Texas Medical Branch.

Correspondence to: William J. Calhoun, MD, 4.118 JSA, Rt 0568, University of Texas Medical Branch, Galveston, TX 77555-0568; e-mail: William.Calhoun@utmb.edu


Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Dr Calhoun has served as a consultant for Genentech, which manufactures the trade drug, Xolair (omilizumab). Dr Bhat has reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.

Funding/Support: The authors are supported in part by the National Center for Research Resources, National Institutes of Health [Grant 1UL1RR029876-01].

Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (http://www.chestpubs.org/site/misc/reprints.xhtml).


© 2011 American College of Chest Physicians


Chest. 2011;139(1):8-10. doi:10.1378/chest.10-2216
Text Size: A A A
Published online

Extract

Asthma is an inflammatory disorder of the airways that affects approximately 300 million people worldwide. A significant number of these patients, estimated at 10% to 15%, have severe disease that is mechanistically heterogeneous and poorly controlled by conventional therapy. Patients with severe asthma are challenging for clinicians because of complex and arcane pathogenic mechanisms, frequent exacerbations, chronic impairment of lung function, and unpleasant medication side effects. This therapeutic gap has sparked the development of novel approaches to care.

First Page Preview

View Large
First page PDF preview

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

MEMBER & INDIVIDUAL SUBSCRIBER

Want Access?

NEW TO CHEST?

Become a CHEST member and receive a FREE subscription as a benefit of membership.

Individuals can purchase this article on ScienceDirect.

Individuals can purchase a subscription to the journal.

Individuals can purchase a subscription to the journal or buy individual articles.

Learn more about membership or Purchase a Full Subscription.

INSTITUTIONAL ACCESS

Institutional access is now available through ScienceDirect and can be purchased at myelsevier.com.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
Guidelines
Omalizumab for severe persistent allergic asthma.
National Institute for Health and Clinical Excellence (NICE) | 1/31/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543